2Seventy Bio

2Seventy Bio CapEx/OCF

Delisted

The CapEx to Operating Cash Flow Ratio of 2Seventy Bio (TSVT) as of Nov 17, 2026 is -0.83 %. In the previous year, CapEx to Operating Cash Flow Ratio was -8.31 % — a change of -89.99% (higher).

CapEx/OCF

-0.83 %

YoY

-89.99%

Last updated:

CapEx to Operating Cash Flow Ratio of 2Seventy Bio is 2024 -0.83 % . CapEx to Operating Cash Flow Ratio of 2Seventy Bio was 2023 -8.31 % . It decreases by -89.99% higher compared to the previous year.

The 2Seventy Bio CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-34.76 USD
Jan 1, 2019
-28.74 USD
Jan 1, 2020
-32.84 USD
Jan 1, 2021
-9.45 USD
Jan 1, 2022
-9.63 USD
Jan 1, 2023
-8.31 USD
Jan 1, 2024
-0.83 USD
The 2Seventy Bio CapEx/OCF history
YEARCapEx/OCFYoY
-0.83 %-89.99%
-8.31 %-13.74%
-9.63 %+1.88%
-9.45 %-71.21%
-32.84 %+14.26%
-28.74 %-17.33%
-34.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2seventy Bio, Inc. generates revenue through its cell and gene therapy programs, including SC-DARIC33 for pediatric relapsed and refractory acute myeloid leukemia and bbT369 for B-cell non-Hodgkin lymphoma. The company collaborates with Bristol Myers Squibb to deliver Abecma for multiple myeloma patients in the U.S., leveraging its T cell engineering and lentiviral vector technologies. Its clinical and preclinical programs, such as bbT4015 targeting MUC16, form the core of its product pipeline. The company focuses on developing targeted cellular therapies for cancer patients, with Bristol Myers Squibb as a key partner in commercializing Abecma. 2seventy Bio, Inc. operates in the biopharmaceutical sector, targeting patients with specific cancer types through its advanced therapies. Its products are developed using proprietary T cell engineering and lentiviral vector delivery systems. The company's revenue streams include clinical trial partnerships and potential future commercial sales of its therapies. Bristol Myers Squibb supports the U.S. distribution of Abecma, a key product in its portfolio. 2Seventy Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2Seventy Bio stock

CapEx to Operating Cash Flow Ratio of 2Seventy Bio is -0.83 % in 2024.

CapEx to Operating Cash Flow Ratio of 2Seventy Bio changed from -8.31 % to -0.83 %, representing a -89.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio 2Seventy Bio since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's 2Seventy Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — 2Seventy Bio

All Key Metrics — 2Seventy Bio